It’s Official: See Why (MBRX) Just Hit Our Early Morning Watchlist

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Jeff Ackerman Just Announced (MBRX) Is Back At The Top Of This Morning's Watchlist—For Wednesday, February 18, 2026 Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Full Coverage Starts Right Now Take A Look At (MBRX) While It's Still Early…… February 18, 2026 It's Official | See Why (MBRX) Just Hit Our Early Morning Watchlist Dear Reader, One little-known company is making significant strides in developing next-generation therapies designed to tackle some of the most aggressive and overlooked cancers. Through a growing lineup of advanced candidates and strategic collaborations with leading research institutions, this organization is redefining what's possible in targeted cancer treatment. Early data highlights strong potential across multiple indications, supported by regulatory designations that accelerate development. As it advances toward key milestones, this company is rapidly gaining attention within the scientific community. Which is why Moleculin Biotech, Inc. (Nasdaq: MBRX) is topping our watchlist this morning—Wednesday, February 18, 2026. But keep in mind, (MBRX) has less than 3M shares listed in its public float, according to MarketWatch. When companies have small floats like this, the potential exists for big moves if demand begins to shift. With multiple near-term milestones ahead and a growing spotlight on its clinical progress, (MBRX) could start to show up on more screens. And with such a small float, it doesn't take much new attention to change the tone in a hurry. Analyst Coverage (Targets Suggest 300% - 600% Upside Potential) According to TipRanks, several firms and analysts have recently initiated or reiterated coverage on (MBRX) with targets that suggest triple-digital upside potential. Sara Nik, an analyst at H.C. Wainwright, set a $22 target on (MBRX) which suggests over 400% upside potential from its recent $4.33 range. Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, set a $20 target on (MBRX), which suggests over 360% upside potential. Jonathan Aschoff, of Roth MKM, set a $31 target on (MBRX), which suggests over 600% upside potential from its recent range. Recent News & Key Milestones February 17, 2026: (MBRX) announced a Notice of Allowance for a Japanese patent covering proprietary methods for reconstituting and preparing liposomal Annamycin. This reinforces the company's international intellectual property moat in a major global pharmaceutical market. January 13, 2026: An independent assessment confirmed no evidence of cardiotoxicity in 90 subjects treated across five trials, validating the "next-generation" safety profile of Annamycin. January 12, 2026: Management accelerated its 2026 outlook, confirming that the first unblinding of the MIRACLE trial is on track for Q1 2026 and that global expansion now spans nine countries. December 17, 2025: Positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors were published, demonstrating safety and anti-tumor immune responses. December 09, 2025: (MBRX) announced the completion of treatment for the first 45 subjects in its pivotal MIRACLE trial, with recruitment pacing reaching 78% consented. Keep reading to see why (MBRX) just landed back on our radar… Moleculin Biotech, Inc. (Nasdaq: MBRX) (MBRX) is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and vi-rus-es. Annamycin: Next Generation Non-Cardiotoxic and Organotropic Anthracycline Annamycin is a next-generation anthracycline being evaluated in the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial, a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia (AML). If successful, Annamycin has the potential to transform the standard of care for 2nd line AML. Annamycin is also in development for the treatment of soft tissue sarcoma (STS). The company believes anthracyclines are among the most important treatments for AML and advanced STS. However, cardiotoxicity issues limit their effectiveness with life-time maximum dosing set by the US FDA. Annamycin has demonstrated in multiple clinical trials a lack of cardiotoxicity, allowing Moleculin to exceed the currently set maximum lifetime dosing for an anthracycline and potentially realizing the full therapeutic potential of anthracyclines to treat serious, hard-to-treat cancers. In addition to demonstrating a lack of cardiotoxicity in patients treated in Moleculin trials to date, Annamycin is demonstrating to have superior efficacy in 2nd line AML compared to currently available treatments. Key Highlights: Potential to be safer and more effective than current prescribed anthracyclines Non-cardiotoxic and avoids cross resistance with doxorubicin, cytarabine (Ara-C) and Venetoclax Delivers more than double the Complete Response (CR) rate of any approved treatment for relapsed/refractory acute myeloid leukemia US FDA Orphan Designation for STS Lung Mets and AML U.S. FDA Fast Track Status for STS Lung Mets MIRACLE: Pivotal, Adaptive Phase 3 Trial in Acute Myeloid Leukemia The MIRACLE study is being run in stages, and the plan could be adjusted based on feedback from U.S. and international regulators. In the first stage, about 75–90 people will receive high-dose cytarabine with either a placebo or one of two FDA-recommended Annamycin dose levels. After the first 45 people, the company plans an early check on response results and how well treatment is tolerated, with another review planned after the next 30–45 people. In the next stage, about 244 more people would receive chemotherapy plus placebo or chemotherapy plus the best-performing Annamycin dose from earlier results to confirm findings with a larger group. The updated protocol is under IRB review, and once cleared, it will be submitted as an amendment to the U.S. IND filing. Annamycin has FDA Fast Track and Orphan designations for relapsed/refractory AML, FDA Orphan designation for soft tissue sarcoma, and an EMA Orphan designation for relapsed/refractory AML. Potential Accelerated Timeline Find Key Sources And More: MBRX Website. MBRX Presentation. 7 Reasons Why (Nasdaq: MBRX) Is Topping Our Watchlist This Morning—Wednesday, February 18, 2026 1. Low Float: With fewer than 3M shares in its public float, (MBRX) sits in a structure where relatively small shifts in buying interest can lead to outsized price swings. 2. Analyst Coverage: Published targets of $20, $22, and $31 on (MBRX) suggests 360% to 600% upside potential from the recent $4.33 range. 3. Phase 3 Status: As a Phase 3 clinical-stage company, (MBRX) is advancing its MIRACLE trial in relapsed or refractory AML, placing it in a late-stage development category. 4. Near-Term Data: Management has stated that the first MIRACLE unblinding remains on track for Q1 2026, giving (MBRX) a defined upcoming clinical checkpoint. 5. Regulatory Support: Fast Track and multiple Orphan designations from the FDA and EMA provide (MBRX) with recognized regulatory backing in AML and soft tissue sarcoma. 6. Cardiac Safety Profile: An independent review reported no evidence of cardiotoxicity in 90 subjects treated across five trials involving Annamycin at (MBRX). 7. Global Expansion: The MIRACLE study tied to (MBRX) now spans nine countries, with 78% of the first 45 subjects consented and treatment completed for that initial group. Take A Look At (MBRX) While It's Still Early… Put it all together, and (MBRX) checks several boxes that research-focused readers look for in an early-stage oncology name: a very small public float of fewer than 3M shares, multiple published analyst targets that have been described as implying roughly 360% to 600% upside potential from the recent $4.33 range, and a late-stage Phase 3 program moving through the MIRACLE trial in relapsed or refractory AML. Add in a clearly defined near-term milestone with the first MIRACLE unblinding expected in Q1 2026, recognized Fast Track and Orphan designations from the FDA and EMA, and an independent assessment reporting no evidence of cardiotoxicity across 90 subjects—plus a trial footprint now spanning nine countries—and it's easy to see why (MBRX) is back on the radar. We have all eyes on (MBRX) this morning—Wednesday, February 18, 2026 Take a look at (MBRX) while it's still early. Also, keep a lookout for my next update, it could be hitting before the bell rings. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com ("StockNewsTrends" or "SNT" ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 02/18/2026 and ending on 02/18/2026 to publicly disseminate information about (MBRX:US) via digital communications. Under this agreement, JRZ Capital LLC has paid TD Media LLC thirty five thousand USD ("Funds"). To date, including under the previously described agreement, TD Media LLC has been paid two hundred six thousand USD ("Funds"). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (MBRX:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/mbrx-o6dqV/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe Update Profile | Constant Contact Data Notice Sent by jeff@stocknewstrends.com